Thomas Nusbickel - 18 Feb 2022 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role
EVP, Chief Commercial Officer
Signature
/s/ Thomas Nusbickel
Issuer symbol
CRMD
Transactions as of
18 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 15:14:08 UTC
Previous filing
20 May 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRMD Stock Option (Right to Buy Common Stock) Award $0 +100,000 $0.000000 100,000 18 Feb 2022 Common Stock 100,000 $4.03 Direct F1
holding CRMD Stock Option (Right to Buy Common Stock) 260,000 18 Feb 2022 Common Stock 260,000 $7.56 Direct F2
holding CRMD Stock Option (Right to Buy Common Stock) 7,500 18 Feb 2022 Common Stock 7,500 $7.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F2 The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment.
F3 These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment.